Cormorant Asset Management’s Clearside Biomedical CLSD Stock Holding History

Cormorant Asset Management’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-26,667	Closed	-$2.46M	–	72
2018 Q3	$2.46M	Sell	26,667 -53,333	-67%	-$6.34M	0.16%	61
2018 Q2	$12.8M	Sell	80,000 -45,392	-36%	-$7.65M	0.95%	32
2018 Q1	$20.2M	Sell	125,392 -4,000	-3%	-$487K	1.5%	18
2017 Q4	$13.6M	Hold	129,392	–	–	1.42%	23
2017 Q3	$17M	Hold	129,392	–	–	3%	10
2017 Q2	$17.7M	Hold	129,392	–	–	2.93%	13
2017 Q1	$15.4M	Sell	129,392 -26,164	-17%	-$3.09M	2.24%	15
2016 Q4	$20.9M	Buy	155,556 +23,009	+17%	+$5.78M	2.81%	13
2016 Q3	$34.5M	Hold	132,547	–	–	3.8%	6
2016 Q2	$13.9M	Buy	+132,547	New	+$13.9M	1.98%	17

Other funds holding CLSD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cormorant Asset Management's CLSD Position: Q4 2018 in Review

Cormorant Asset Management sold out of Clearside Biomedical (CLSD) in Q4 2018, closing a stake of 26,667 shares — an estimated $2.46M sold.

Cormorant Asset Management first reported a position in CLSD in Q2 2016 and held it in 10 quarters. The position peaked at $34.5M in Q3 2016. 69 funds tracked by Wall St. Rank hold CLSD as of Q4 2018.

Cormorant Asset Management reported no remaining Clearside Biomedical position as of Q4 2018 after selling out during the quarter.
Cormorant Asset Management sold 26,667 Clearside Biomedical shares in Q4 2018, an estimated $2.46M.
Cormorant Asset Management first reported a position in Clearside Biomedical in Q2 2016 and held it in 10 quarters.
Cormorant Asset Management's Clearside Biomedical position peaked at $34.5M in Q3 2016.
69 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2018.

Based on Cormorant Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.